Investor Presentaiton
INVESTOR 20
DAY 23
ASCO Daily News
Clinical News From the American Society of Clinical Oncology
Real-World Analysis Shows Utility of ctDNA Kinetics in
Patients With Advanced Colorectal Cancer
Real-world
evidence from
GuardantINFORM
has been
successfully used
to validate novel
signatures
10-
0.8
0.6
0.4
0.2
0.0
-responder
-nonresponder
10-
0
200
400
600
800
1000
1200
timeline
0.8
0.6
0.41
20
0.2-
responder
nonresponder
0.0-
0
100
200
300
400
500
600
timeline
Kaplan-Meier in molecular responders vs non-responders for patients
receiving chemotherapy +/- VEGF.
GUARDANT™
Kasi et al. Use of circulating tumor DNA (ctDNA) for early assessment of treatment response in patients
with advanced colorectal cancer (mCRC): A real-world (RW) analysis. ASCO GI, 2023
159View entire presentation